BenzingaOctober 25, 2026 at 10:58 PM NYYesterday
Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
